- Verona Pharma announces regulatory approval in five European countries for a Phase 2b dose-ranging trial of RPL554 for maintenance treatment of chronic obstructive pulmonary disease (COPD).

The countries were UK, Germany, Romania, Bulgaria, and Czech Republic.

The trial was expected to commence in the third quarter of 2017, with top-line data expected in the second half of 2018.

RPL554 was a first-in-class, inhaled, dual inhibitor of the enzymes phosphodiesterase 3 and 4 designed to have anti-inflammatory as well as bronchodilator properties, and is currently in development for the treatment of COPD and cystic fibrosis.

This double-blind, placebo-controlled, parallel group, four-week trial would investigate the efficacy, safety, and dose-response of nebulized RPL554 for the maintenance treatment of COPD across approximately 400 people with the disease in the five countries.

The primary endpoint is evaluating improvement in lung function with RPL554 compared with placebo, as measured by FEV1, a standard measure of exhaled breath volume used to evaluate respiratory function.

Story provided by